Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atazanavir + cobicistat
- Development stage
- Approved
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Atazanavir + cobicistat** is an oral fixed-dose antiretroviral combination marketed as **Evotaz**. It contains atazanavir, an HIV-1 protease inhibitor that prevents proteolytic processing of viral Gag and Gag-Pol polyproteins and thereby blocks production of mature infectious virions, plus cobicistat, a CYP3A inhibitor used as a pharmacokinetic enhancer to raise and maintain atazanavir exposure. It is used with other antiretroviral medicines for treatment of HIV-1 infection in adults and eligible pediatric patients weighing at least 35 kg. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83db29d7-5d85-49d6-8cb6-740473365cf8))
- Brand names
- Evotaz
- Other names
- ATV/catazanavir + cobicistatatazanavir/cobicistatcobicistat + atazanavircobicistat/atazanavir
02
Targets
CYP3A4 (Cytochrome P450 3A4)PR (Progesterone receptor)
Beyond the preview
Go deeper on atazanavir + cobicistat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atazanavir + cobicistat.